These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22419641)

  • 1. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
    J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
    Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
    Menzies D; Adjobimey M; Ruslami R; Trajman A; Sow O; Kim H; Obeng Baah J; Marks GB; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Gninafon M; Apriani L; Koesoemadinata RC; Kritski A; Rolla V; Bah B; Camara A; Boakye I; Cook VJ; Goldberg H; Valiquette C; Hornby K; Dion MJ; Li PZ; Hill PC; Schwartzman K; Benedetti A
    N Engl J Med; 2018 Aug; 379(5):440-453. PubMed ID: 30067931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
    Yang H; Yang Y; Hu ZD; Xia L; Liu XH; Yu X; Ma JY; Li T; Lu SH
    PLoS One; 2021; 16(6):e0253159. PubMed ID: 34115804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Side Effects of Rifampin versus Isoniazid in Children.
    Diallo T; Adjobimey M; Ruslami R; Trajman A; Sow O; Obeng Baah J; Marks GB; Long R; Elwood K; Zielinski D; Gninafon M; Wulandari DA; Apriani L; Valiquette C; Fregonese F; Hornby K; Li PZ; Hill PC; Schwartzman K; Benedetti A; Menzies D
    N Engl J Med; 2018 Aug; 379(5):454-463. PubMed ID: 30067928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.